Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2021-03-13
Target enrollment:
Participant gender:
Summary
Target therapy with sorafenib is the standard of treatment for advanced Hepatocellular
carcinoma (HCC), but the patient survival time is still unsatisfactory. The aims of this
study are to prove statins improve the tumor responses and overall survival for patients who
receive sorafenib therapy for advanced HCC by a prospective randomized controlled study.